Blog hero background graphic

Blog

The Beghou Biopharma Review

Why reps ignore HQ's guidance; 3 questions for oncology sales veteran Perry Monaco

Why pharma reps distrust HQ guidance and how to fix it. Data from Beghou's Field Force Pulse Survey plus insights from oncology sales...

Why reps ignore HQ's guidance; 3 questions for oncology sales veteran Perry Monacofeatured image

Dashboard discord: 5 reasons pharma reps ignore HQ guidance

Turning individual AI experimentation into sustained adoption and value in life sciences

The last operational mile in life sciences commercialization: Five questions you need to ask of your commercial decision system

Opinion: CAR Ts will only treat autoimmune diseases if we can scale delivery

When payers know the price of everything

From commercialization data foundation to launch advantage

Fast 5: Why did Merck just temper expectations for its oral PCSK9 launch?

Four strategies for winning, not just reaching, the biotech launch stage

The Space Life Sciences Podcast

Oncology confidential: candid perspectives from a 28-year oncology sales veteran

The Beghou Biopharma Review

The conference season, distilled, in this summer debrief

Threat from within: Why biopharma's drug development bottleneck is systemic

The physician feedback loop: What HCPs are telling pharma and healthcare market research

The Beghou Biopharma Review

H1’s most consequential commercialization trends; 3 questions for Star Therapeutics’ Jacob Lai

Why Medical Affairs must be integrated into field strategy

Making AI work for your first launch: Where it drives commercial and medical impact, and where it doesn't